BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21445018)

  • 21. High-definition chromocolonoscopy vs. high-definition white light colonoscopy for average-risk colorectal cancer screening.
    Kahi CJ; Anderson JC; Waxman I; Kessler WR; Imperiale TF; Li X; Rex DK
    Am J Gastroenterol; 2010 Jun; 105(6):1301-7. PubMed ID: 20179689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates.
    Segnan N; Senore C; Andreoni B; Arrigoni A; Bisanti L; Cardelli A; Castiglione G; Crosta C; DiPlacido R; Ferrari A; Ferraris R; Ferrero F; Fracchia M; Gasperoni S; Malfitana G; Recchia S; Risio M; Rizzetto M; Saracco G; Spandre M; Turco D; Turco P; Zappa M;
    J Natl Cancer Inst; 2005 Mar; 97(5):347-57. PubMed ID: 15741571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Colonoscopic surveillance of first-degree relatives of colorectal cancer patients in a faecal occult blood screening programme.
    Sassoli de Bianchi P; Campari C; Mancini S; Giuliani O; Landi P; Paterlini L; Naldoni C; Finarelli AC; Falcini F; Ponz de Leon M; Sassatelli R; Borciani E; Fornari F; Gatti G; Zatelli M; Zurlini C; Rossi F; Corradini R; Olivetti R; Manfredi M; Baldazzi P; Nannini R; Zanarini S; Matarese VG; Palmonari C; Triossi O; Gordini S; Vattiato R; Colamartini A; Palazzi M; Severi M; Briganti L; Giovanardi M; Casale C; Bucchi L
    Cancer Epidemiol; 2013 Aug; 37(4):469-73. PubMed ID: 23683843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early detection of colorectal cancer with faecal occult blood test screening.
    Paimela H; Malila N; Palva T; Hakulinen T; Vertio H; Järvinen H
    Br J Surg; 2010 Oct; 97(10):1567-71. PubMed ID: 20603855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the sensitivity of an immunochemical fecal occult blood test for colorectal neoplasia.
    Yoshinaga M; Motomura S; Takeda H; Yanagisawa Z; Ikeda K
    Am J Gastroenterol; 1995 Jul; 90(7):1076-9. PubMed ID: 7611200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.
    Tsoi KK; Ng SS; Leung MC; Sung JJ
    Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening.
    Segnan N; Senore C; Andreoni B; Azzoni A; Bisanti L; Cardelli A; Castiglione G; Crosta C; Ederle A; Fantin A; Ferrari A; Fracchia M; Ferrero F; Gasperoni S; Recchia S; Risio M; Rubeca T; Saracco G; Zappa M;
    Gastroenterology; 2007 Jun; 132(7):2304-12. PubMed ID: 17570205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High uptake of colonoscopy in first-degree relatives of patients with colorectal cancer in a healthcare region: a population-based, prospective study.
    Armelao F; Orlandi PG; Tasini E; Franceschini G; Franch R; Paternolli C; de Pretis G
    Endoscopy; 2010 Jan; 42(1):15-21. PubMed ID: 20066589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Colorectal cancer screening for the natural population of Beijing with sequential fecal occult blood test: a multicenter study.
    Li S; Nie Z; Li N; Li J; Zhang P; Yang Z; Mu S; Du Y; Hu J; Yuan S; Qu H; Zhang T; Wang S; Dong E; Qi D
    Chin Med J (Engl); 2003 Feb; 116(2):200-2. PubMed ID: 12775229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up.
    Scholefield JH; Moss SM; Mangham CM; Whynes DK; Hardcastle JD
    Gut; 2012 Jul; 61(7):1036-40. PubMed ID: 22052062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].
    Quintero E
    Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).
    Hoff G; Grotmol T; Thiis-Evensen E; Bretthauer M; Gondal G; Vatn MH
    Gut; 2004 Sep; 53(9):1329-33. PubMed ID: 15306594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can patients at high risk for significant colorectal neoplasms and having normal quantitative faecal occult blood test postpone elective colonoscopy?
    Hazazi R; Rozen P; Leshno M; Levi Z; Samuel Z; Waked A; Vilkin A; Maoz E; Birkenfeld S; Niv Y
    Aliment Pharmacol Ther; 2010 Feb; 31(4):523-33. PubMed ID: 19925498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer?
    Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Niv Y
    Aliment Pharmacol Ther; 2006 Nov; 24(10):1475-81. PubMed ID: 17032281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implementation of colorectal cancer screening in Finland: experiences from the first three years of a public health programme.
    Malila N; Oivanen T; Hakama M
    Z Gastroenterol; 2008 Apr; 46 Suppl 1():S25-8. PubMed ID: 18368636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening for gastrointestinal neoplasia: efficacy and cost of two different approaches in a clinical rehabilitation centre.
    Manus B; Brägelmann R; Armbrecht U; Stolte M; Stockbrügger RW
    Eur J Cancer Prev; 1996 Feb; 5(1):49-55. PubMed ID: 8664809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measuring the quality of colorectal cancer screening: the importance of follow-up.
    Etzioni DA; Yano EM; Rubenstein LV; Lee ML; Ko CY; Brook RH; Parkerton PH; Asch SM
    Dis Colon Rectum; 2006 Jul; 49(7):1002-10. PubMed ID: 16673056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Evaluating colorectal cancer screening strategies (immunological test vs biochemical test) in Catalonia, Spain 2008-2010].
    García Martínez M; Binefa Rodríguez G; Milà Díaz N; Rodríguez Moranta F; Gonzalo Diego N; Muñoz Sánchez C; Espinàs Piñol JA; Borràs Andrés JM; Moreno Aguado V
    Rev Esp Salud Publica; 2011 Dec; 85(6):593-602. PubMed ID: 22249590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An analysis of the duplicate testing strategy of an Irish immunochemical faecal occult blood test colorectal cancer screening programme.
    Kelley L; Swan N; Hughes DJ
    Colorectal Dis; 2013 Sep; 15(9):e512-21. PubMed ID: 23746062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.
    Imperiale TF; Ransohoff DF; Itzkowitz SH; Turnbull BA; Ross ME;
    N Engl J Med; 2004 Dec; 351(26):2704-14. PubMed ID: 15616205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.